BridgeBio's Oral Infigratinib Shows Benefits Beyond Growth Achondroplasia Phase 3 PROPEL 3 Trial

BridgeBio Pharma reported exploratory results from its pivotal Phase 3 PROPEL 3 trial indicating that infigratinib delivered meaningful benefits beyond growth in children with achondroplasia within 52 weeks. The positive clinical update supports the therapeutic potential of the ongoing program and could be a catalyst for BridgeBio shares, although no detailed efficacy or safety metrics were disclosed.